Private Neurology Companies: Back In The Saddle Again
This article was originally published in Start Up
Executive Summary
START-UP reviews five years of fundraising and exit activities for privately held biopharma companies developing neurology treatments. Next month we’ll delve into neurology medtech and diagnostics companies’ capital-raising and bow-outs.